RevBio, Inc.

The RevBio team completed three successful industry conference stops on the “2026 Bone Glue Roadshow” where they showcased TETRANITE® in various late-stage clinical trials! Head to our LinkedIn to read the full post!

CEO Brian Hess and Director of Product and Clinical Development, Brittany McDonough, kicked off the week by attending the American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting in New Orleans. The focus of this conference was to raise awareness and build excitement for our upcoming clinical pilot study to evaluate TETRANITE for extremity fracture fixation. 

The next stop was the Academy of Osseointegration (AO) 2026 Annual Meeting in Washington, DC. The team hosted an evening event where clinicians and industry leaders were able to learn about the various TETRANITE® applications, both within the dental space and beyond. Special emphasis was placed around building excitement for our pivotal study for dental implant stabilization. Day two of the meeting featured a Town Hall presentation by RevBio CFO/COO D. Grayson Allen, Sr. Director of Dental Clinical Operations, Dr. Alan Pollack, and Marketing Director, Michael Tiedemann. Thank you to everyone who attended our event and presentation—what a great turn out!

The team’s travels concluded with the North American Skull Base Society ( ) 2026 Annual Meeting in San Diego, California. CEO Brian Hess, VP of R&D Michael Brown, Clinical Development Specialist, Gracie Cleaver, and Marketing Specialist, Erica Malho, manned the booth and provided TETRANITE® product demonstrations to interested clinicians. Attendees were excited to learn about our upcoming pivotal clinical trial which will evaluate TETRANITE to fixate cranial flaps after craniotomy procedures.

And the momentum isn’t slowing down! We thank our team and collaborators for their continued efforts… RegenerativeBoneAdhesive

What a great time at the Yankee Dental Congress in Boston last week!

RevBio was one of only five companies to be featured in the “Liquid Gold Exhibit” by Revere Partners. This exhibit highlighted cutting-edge startups driving the future of dentistry. We had meaningful conversations with attendees regarding how TETRANITE® is disrupting to the standard of care in dentistry, as well our Series A funding round. The team also demonstrated two TETRANITE dental products: Implant Stabilization Material and Adhesive Dental Bone Scaffold.

It was great seeing some familiar faces, including RevBio Dental Advisor Board member Dr. Alvaro Gracia and Bruce Kennedy from our Dental Sales Team.

Thank you to everyone who stopped by to connect and learn how TETRANITE is transforming dentistry for clinicians and patients alike. And a big thanks to Revere Partners and Jeremy N. Krell, DMD, MB for having us!

RevBio® is proud to announce another watershed moment for our Cranial Flap Fixation program—FDA has greenlighted us for a pivotal clinical trial!

The company has received investigational device exemption (IDE) approval from the FDA to conduct a multi-center randomized controlled pivotal clinical trial to use ® to reintegrate cranial bone flaps, which are portions of the skull that are temporarily removed by neurosurgeons to perform brain surgery.

“This regenerative adhesive has the potential to fundamentally change how cranial reconstruction is performed. It enhances structural integrity, promotes fusion, reduces wound complications, and delivers markedly improved cosmetic outcomes,” said Timothy Smith, MD, PhD, MPH, Director, Computational Neuroscience Outcomes Center and practicing neurosurgeon at Brigham and Women’s Hospital in Boston, Massachusetts.

Check out the full press release, here–https://www.businesswire.com/news/home/20260127271652/en/FDA-Greenlights-RevBios-Pivotal-Clinical-Trial-for-its-Cranial-Flap-Bone-Glue

Craniotomy Cranioplasty Kerf Fixation RegenerativeMedicine BoneRegeneration ClinicalTrial PivotalTrial NovelTechnology FDA IDEapproval

RevBio is excited to share that CEO Brian Hess and CFO Grayson Allen will be representing the company at the 2025 New England Venture Summit, hosted by youngStartup Ventures.
 
We’re honored to have been selected to present TETRANITE®, our groundbreaking regenerative bone glue, as a significant investment opportunity to an audience of venture capitalists, corporate and private investors, investment bankers, and strategic partners across the MedTech industry. With our pivotal clinical trial for cranial flap fixation on the horizon, the time is now to focus our efforts on raising Series A capital to bring our game-changing technology to market supported by the promising pilot study results.
 
Don’t miss CEO Brian Hess on the MedTech Track as he showcases RevBio’s clinical trial updates and the TETRANITE product pipeline on Wednesday, December 10th at 11:40 AM EST in the New England Suite.
 
Recognized as a premier gathering for innovators and investors, NEVS brings together leaders seeking new opportunities, strategic visibility, and growth. Learn more about Young Startup Ventures and register for upcoming events here: https://www.youngstartup.com

CEO Brian Hess and CFO Grayson Allen represented RevBio at the Musculoskeletal New Ventures Conference (MNVC) in Memphis, TN. While there, Brian shared exciting company updates and presented clinical trial progress across a range of indications to an audience of surgeons, investors, and industry leaders. Easily injectable into a range of musculoskeletal defects, TETRANITE® has demonstrated superior clinical performance over current standard of care options including curing speed, shear forces, rate of bone regeneration, and most critically, wet-field adhesion.
 
This marks RevBio’s fifth year attending MNVC, a cornerstone event for innovation in the musculoskeletal field. We’re always inspired by the opportunity to connect, collaborate, and explore the latest advancements shaping the future of musculoskeletal health. Thank you to Gary Stevenson and HealthpointCapital for organizing this great event.